Quarterly ResultJul 16, 2026, 07:41 AM
Abbott Q2 Adjusted EPS $1.31; Raises Full-Year Guidance
AI Summary
Abbott Laboratories announced strong second-quarter 2026 results, with reported sales growth of 13.0% and adjusted diluted EPS of $1.31. The company raised its full-year 2026 adjusted diluted EPS guidance to $5.45-$5.60, reflecting continued momentum. Key business segments like Medical Devices and Diagnostics showed solid comparable sales growth, while the company also returned $2.1 billion to shareholders and achieved significant product milestones, including a CE Mark for its Libre® Duo sensor.
Key Highlights
- Reported Q2 2026 adjusted diluted EPS of $1.31, up 4.0% from Q2 2025.
- Q2 2026 reported sales grew 13.0% to $12.59 billion; comparable sales grew 4.8%.
- Raised full-year 2026 adjusted diluted EPS guidance range to $5.45-$5.60.
- Medical Devices comparable sales increased 8.4%, led by Electrophysiology and Diabetes Care.
- Diagnostics comparable sales grew 2.9%, driven by 13.3% growth in Cancer Diagnostics.
- Returned $2.1 billion to shareholders in Q2 through dividends and share repurchases.
- Secured CE Mark for Libre® Duo, the world's first dual glucose-ketone biowearable sensor.
Price Impact
More from ABT